NanosiRNA® COVID-19: specific antiviral treatment Medesis Pharma has a microemulsion
Medesis Pharma is developing a radioprotection drug to treat people irradiated following
Alzheimer’s disease is the most frequent cause of dementia and one of the most
The objective of the radioprotection program is to develop a radiomitigation drug,
NU02 Cesium decorporation 137Cs is gamma and beta emitting by-product of uranium
AONYS® is a mix of lipidic components that spontaneously assemble into a water-in-oil
NanoLithium® (NP03) is a disease-modifying nano dose formulation of lithium citrate
NU01 Plutonium decorporation Plutonium (Pu) is an alpha emitting radionuclide which
Huntington’s Disease (HD) is a fatal autosomal dominant progressive neurodegenerative
